Biomarkers, uses of biomarkers and a method of identifying biomarkers

The invention relates to the use of one or more of protein myoferlin, protein latent-transforming growth factor beta binding protein2, protein transforming growth factor beta induced protein ig-h3, protein asporin, protein tenascin, protein periostin, protein galectin, protein fibronectin, protein prolargin, protein protein-glutamine gamma-glutamyl, transferase 2, protein agrin, protein adipocyte enhancer-binding protein 1, protein annexin A6, protein laminin alpha-2 subunit, protein laminin subunit alpha-4, protein mimecan, protein Ras-related protein Rap-2b, protein collagen alpha-1 (XrV) chain, protein, collagen alpha-3 (VI) chain, protein latent-transforming growth factor beta binding protein 1, protein V type proton ATPase catalytic subunit A, protein laminin alpha-4 and protein transmembrane protein 62 as a biomarker for pancreatic cancer, or a predisposition thereto. The invention also relates to ligands directed to the above-mentioned biomarkers, for use in the therapeutic and/or prophylactic treatment of a pancreatic cancer.